Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
As of today, Johnson & Johnson(JNJ) shares are valued at $219.50. The company's market cap stands at 529.03B, with a P/E ratio of 20.62 and a dividend yield of 2.4%.
On 2026-01-16, Johnson & Johnson(JNJ) stock traded between a low of $215.91 and a high of $219.75. Shares are currently priced at $219.50, which is +1.7% above the low and -0.1% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 8.49M, against a daily average of 8.77M.
During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $219.75 at its peak.
During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $219.75 at its peak.
JNJ News
ORIC Pharmaceuticals (ORIC) stock has been in focus after fresh buy ratings from several research firms coincided with encouraging trial updates for its lead on...
Johnson & Johnson recently reported positive topline Phase 3 MajesTEC-9 results showing TECVAYLI monotherapy improved progression-free and overall survival vers...
Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple my...
Analyst ratings
56%
of 27 ratingsMore JNJ News
In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $213.83, changing hands for $218.61...
Johnson & Johnson announced positive topline results from the investigational Phase 3 MajesTEC-9 study of tecvayli – teclistamab-cqyv – monotherapy, showing a 7...
If you are wondering whether Johnson & Johnson is still reasonably priced after its recent run, this article will walk through what the current share price migh...
Claim 70% Off TipRanks Premium An announcement from Clarity Medical Group Holding Limited ( (HK:1406) ) is now available. Clarity Medical Group Holding Limite...
Johnson & Johnson (NYSE:JNJ) on Monday reportedly secured a partial legal victory after Delaware's highest court overturned a portion of a $1 billion damages aw...
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech s...
On Saturday, Johnson & Johnson (NYSE:JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantam...
